Latest News

MSCI (MSCI) is back in the spotlight as it weighs stricter rules for digital assets in its indexes, including the potential exclusion of companies whose balance sheets rely heavily on cryptocurrencies and digital asset treasuries. See our latest analysis for MSCI. Those tougher digital asset rules land at an interesting time for the stock. A recent 7 day share price return of 3.09 percent has helped to steady what has otherwise been a weak year to date share price return of negative 7.3...

Wanguo Gold Group recently reported past results showing a 42.6% increase in revenue and a Return on Equity of 27.77%, accompanied by technical indicators pointing to oversold conditions and potential for a rebound. The combination of strong profitability metrics and signals of an oversold bounce is drawing fresh attention to how Wanguo’s diversified mining operations fit within the basic materials sector. Next, we will examine how Wanguo’s strong Return on Equity reshapes its investment...

Quipt Home Medical (TSX:QIPT) just posted its FY 2025 third quarter numbers, with revenue of about $58.3 million and a basic EPS of roughly -$0.07 as net income came in at around -$3.0 million. Looking back over recent quarters, the company has kept revenue in a tight band between roughly $57 million and $61 million while EPS has hovered in negative territory, ranging from about -$0.02 to -$0.07. This underscores pressure on margins even as the top line holds steady. For investors, this mix...

Earlier in December 2025, Pharvaris reported pivotal Phase 3 RAPIDe-3 data for its oral deucrictibant capsule in hereditary angioedema (HAE) and confirmed plans to begin global marketing authorization filings, including a U.S. FDA New Drug Application, starting in the first half of 2026. An especially important angle for investors is that, if the ongoing CHAPTER-3 trial is successful, deucrictibant could become the first oral therapy designed to address both on-demand and prophylactic...

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

If you are wondering whether U.S. Bancorp at around $53.71 is still worth buying after its recent run, you are not alone. This piece is going to unpack what the current price really implies about value. The stock has climbed about 4.5% over the last week and 14.0% in the past month, building on a 12.2% gain year to date and roughly 9.3% over the last year. This hints that the market is slowly warming back up to the name after a choppy few years. Recent headlines have focused on the health of...

If you are wondering whether Arm Holdings is attractively priced today or whether the excitement is already fully reflected in the share price, you are in the right place to unpack what the market might be missing. After a sharp rally earlier in the year, the stock has recently cooled off, with the price down around 11% over the last week and month, and about 3% lower year to date, leaving it roughly 14.2% below where it was a year ago. These swings come as investors digest Arm’s push deeper...

Market context for Eli Lilly Eli Lilly (LLY) has been quietly grinding higher, with the stock up about 4% over the past month and nearly 39% in the past 3 months, far outpacing the broader market. See our latest analysis for Eli Lilly. That move fits into a powerful run, with a roughly 36.5% year to date share price return and a 37.4% one year total shareholder return. This suggests momentum is still very much building rather than fading. If Lilly’s surge has you rethinking healthcare...

By buying an index fund, investors can approximate the average market return. But many of us dare to dream of bigger...

Murphy USA recently appointed Michael G. Kulp, Founder and CEO of KBP Brands, to its board as an independent Class I director, assigning him to the Audit and Executive Compensation Committees with a term running through the 2026 annual meeting. Kulp’s experience scaling more than 1,200 fast-food restaurant locations through over 95 multi-unit acquisitions may give Murphy USA fresh operational and M&A insights that are highly relevant to a large, efficiency-focused fuel and convenience...

In recent days, Cronos Group has been swept up in reports that the Trump administration may reclassify marijuana from Schedule I to Schedule III in the U.S., a move that would ease federal restrictions and taxation for the cannabis industry. At the same time, Cronos agreed to acquire CanAdelaar B.V., the largest player in the Netherlands’ adult-use cannabis pilot program, signalling a push to build a meaningful European footprint alongside any regulatory shifts in its key North American...

Franco-Nevada (TSX:FNV) is back on investors radar after co founder Pierre Lassonde received a major lifetime achievement award and the company joined the TSX Composite Dividend Index, together spotlighting its royalty model and income profile. See our latest analysis for Franco-Nevada. Those headlines land at a time when sentiment is already tilting in Franco-Nevada’s favor, with a 67.54% year to date share price return and a 73.47% one year total shareholder return signaling strong,...

CRA International (CRAI) has quietly outperformed the broader market over the past month, gaining about 10%, even as its past year has been roughly flat. That combination of steady fundamentals and uneven sentiment may create an interesting point for investors to take a closer look. See our latest analysis for CRA International. With the share price now around $199.19 and a 30 day share price return of just over 10%, the near term momentum stands in contrast to a slightly negative 1 year...

Emera Incorporated recently filed a CAD 600 million at-the-market follow-on equity offering for its common shares and, shortly after, Senior Officer Jared Blake Green acquired 5,000 common shares through direct ownership. The combination of fresh equity capacity and insider buying highlights how Emera’s leadership is aligning personal capital with the company’s long-term capital plan and growth ambitions. With this insider purchase as a focal point, we’ll explore how the new equity program...

Wondering if YETI Holdings is finally at a buyable price, or if the market is still clinging to the brand hype? Let us unpack what the numbers are actually saying about value here. After a choppy few years, the stock has crept higher, up 1.0% over the past week and 16.2% over the last month. That brings its year-to-date gain to 15.6% but leaves the 1-year return almost flat at 0.3%, and the 5-year return still down about 40.0% from earlier highs. Recently, YETI has stayed in the conversation...

Earlier in December 2025, Marqeta, Inc. announced that its Board had authorized a share repurchase program of up to US$100 million of its Class A common stock, with no set expiration date and execution aligned to its capital allocation priorities. This buyback initiative highlights management’s confidence in Marqeta’s underlying business and signals an intention to return excess capital while potentially reducing share count over time. We’ll now examine how Marqeta’s newly announced...

Strategy (MSTR) has quietly slid over the past few months, with the stock down about 19% this month and more than 50% over the past 3 months, despite solid net income growth. See our latest analysis for Strategy. The recent slide is a sharp contrast to Strategy’s multiyear run, with the share price now at $162.08 and short term share price momentum clearly fading, even as longer term total shareholder returns remain impressive. If this shift in sentiment has you reassessing opportunities in...

If you are wondering whether Solstice Advanced Materials is still flying under the radar or already priced for perfection, you are not alone. This stock has quietly moved onto many watchlists. In the last week the share price has climbed 4.5%, and over the past 30 days it is up a solid 12.0%, even though year to date it is only slightly ahead at 0.8%. Much of that recent momentum has followed upbeat commentary around demand for next generation battery materials and new supply agreements with...

Wondering if UiPath at around $16 a share is quietly setting up a bargain, or just another hype name in automation? Let's cut through the noise and focus on what the numbers are really saying about its value. The stock has been choppy lately, sliding about 16.2% over the last week, but still up roughly 15.2% over the past month and 25.0% year to date, which tells you sentiment is shifting fast. Over the last year it is still sitting on a 14.9% gain, and roughly 29.5% higher over three years,...

Willis Towers Watson (WTW) has been quietly grinding higher, with the stock up around 7% this year and roughly flat over the past 3 months, despite mixed profit and revenue growth trends. See our latest analysis for Willis Towers Watson. At around $330.77 per share, Willis Towers Watson’s steady year to date share price return of about 7% and robust five year total shareholder return near 70% suggest momentum is gradually building as investors grow more comfortable with its mixed growth...

QUALCOMM (QCOM) just logged its ninth straight quarter of topping both revenue and EPS expectations, and that consistency is exactly why investors are paying closer attention to the stock right now. See our latest analysis for QUALCOMM. The market seems to be catching on, with QUALCOMM’s share price up 16.68% on a year to date basis and its 3 year total shareholder return of 70.40% reflecting how investors have been rewarding its steady execution, ongoing acquisitions in AI and data center,...

Suncor Energy has released its 2026 corporate guidance, forecasting total production of 840,000 to 870,000 barrels per day, alongside lower capital spending and high refinery utilization of 99% to 102%. The company is pairing this planned production growth with a 10% increase in monthly share buybacks to C$275 million, targeting C$3.30 billion of repurchases in 2026 to reinforce its focus on shareholder returns. Next, we’ll examine how Suncor’s higher 2026 production targets and expanded...

Crown Castle (CCI) has quietly drifted lower over the past month, and that slide is prompting fresh questions about what investors are really paying for in this tower and fiber landlord. See our latest analysis for Crown Castle. That recent 4.4% 3 month share price pullback comes on top of a 1 year total shareholder return of negative 1.7% and a bruising negative 20.8% over three years. This suggests momentum is still fading as investors reassess tower growth and balance sheet risk. If Crown...

Texas Instruments (TXN) has been drifting slightly lower this week, but the bigger story sits beneath the share price. Even with a modest pullback, the chipmaker’s multiyear returns still outpace the broader market. See our latest analysis for Texas Instruments. The recent pullback leaves Texas Instruments’ share price at $177.99, after an 11.71% 1 month share price return that has eased off and a more muted 1 year total shareholder return of negative 3 percent. This suggests momentum is...